Importance: Primary bilateral uveal melanoma (UM) is a rare and incompletely described entity. It is not known how these patients compare to those with unilateral UM.
INTRODUCTION
Ocular melanoma, including melanoma of the uveal tract and conjunctiva, is the most common primary intraocular tumour in adults. 1 Uveal melanoma (UM), occurring at a rate of 4.9 per million in the United States, is the most common type of ocular melanoma.
1,2 UM arises from melanocytes in the choroid, and less commonly, the ciliary body and iris. 2 Genetically, UM differs from cutaneous melanoma, with mutations in GNAQ and GNA11 resulting in MAPK pathway activation, rather than the BRAF and NRAS mutations characteristic of cutaneous melanomas. [3] [4] [5] Moreover, inactivating mutations in BAP1 are frequently observed in metastatic UM, suggesting that loss of BAP1 may be associated with disease progression. 6 UM typically presents as a unilateral tumour in fair-skinned individuals with light-coloured irides. 7 Additional risk factors for UM include male sex, atypical cutaneous nevi, freckles, congenital ocular and oculodermal melanocytosis, uveal nevi and occupational ultraviolet light exposure, particularly in welders. [7] [8] [9] Clinical factors associated with a poor prognosis include increased age, the presence of symptoms at diagnosis, large tumour size, tumour pigmentation and ciliary body involvement. [10] [11] [12] [13] Primary bilateral UM is extremely rare, comprising less than 0.2% of all UM cases diagnosed at a single institution over 30 years. 14 The development of bilateral UM may indicate a genetic predisposition to developing UM given the co-occurrence of malignancy in a paired organ.
14 However, the characteristics of primary bilateral UM and how they relate to unilateral UM, are poorly understood. Therefore, we sought to comprehensively describe the clinicopathological characteristics, treatments and prognoses of patients with primary bilateral UM by identifying cases from an institutional database, a population-based cancer registry and the published literature.
METHODS

Data sources
Cases of primary bilateral UM were obtained from: (i) the University Hospitals Cleveland Medical Center (UHCMC) pathology database (n = 1); (ii) the Surveillance, Epidemiology, and End Results (SEER)-18 database (n = 5) and (iii) a systematic review of well-documented cases reported in the English language literature (n = 46). The Institutional Review Board at UHCMC approved this study.
Institutional database
The UHCMC pathology database from January 1, 1996 to April 15, 2016 was retrospectively reviewed for pathology reports of histologically confirmed melanoma containing the search terms 'uveal', 'choroid', 'ciliary body' or 'iris'. Cases were classified as primary bilateral UM when melanoma was diagnosed in the choroid, ciliary body or iris in both the right and left eye. Cases were excluded if there was suspicion of metastatic disease from the contralateral eye or from a non-ocular primary site.
Population-based cancer registry
The SEER-18 database (released April 15, 2016) of the National Cancer Institute collects observational data, including patient demographics, tumour characteristics, treatments and survival across 18 cancer registry sites from 1973 to 2013. 15 Patients were classified as having UM if the case contained the International Classification of Diseases for Oncology, Third Edition histology code 'nevi and melanomas' (8720-8799), and the primary site code 'choroid' (69.3) or 'ciliary body' (69.4). SEER-18 codes the ciliary body and iris as one combined primary site. Although SEER does not record information regarding tumour size and pigmentation, primary tumour stage was used as a proxy for largest basal diameter (LBD) and tumour thickness. Cases without malignant behaviour or known age were excluded.
Patients were classified as having primary bilateral UM if a primary UM was diagnosed in both the right and left eye in the same patient. Cases of two UM diagnosed within 2 months of each other were considered simultaneous rather than sequential tumours. Patients were classified as having unilateral UM if a primary UM was diagnosed in only the right or left eye. Cases of unilateral UM identified in the SEER-18 database from 1973 to 2013 served as a control group and were compared to cases of primary bilateral UM. Of note, most retinal melanomas within SEER are considered to represent misclassification of UM. 2 The primary site code 'retina' (69.2) revealed no additional cases of bilateral UM and thus was not included in any further analyses.
Systematic review
The systematic review was designed to identify all cases of primary bilateral UM reported in the English language literature. We searched MED-LINE, EMBASE, CINAHL, Cochrane Library, Web of Science and Clinicaltrials.gov from the inception of each database to April 15, 2016 using the keywords 'bilateral ocular melanoma', 'bilateral UM' and 'bilateral choroidal melanoma'. All study designs were included. Duplicate studies were removed based on titles (n = 506), and abstracts were screened and excluded if there was no indication that they described cases of primary bilateral UM (n = 231) or if they were non-English studies (n = 27). Full-texts of the remaining articles were reviewed for inclusion and references from these articles were reviewed by hand to identify any additional studies. Additional exclusion criteria included studies reporting on duplicate cases and studies describing the paraneoplastic syndrome of bilateral diffuse uveal melanocytic proliferation (n = 12). 16, 17 All authors agreed upon the final selection of Bilateral uveal melanoma 503 included studies. Studies were graded according to their quality of evidence using the Oxford Centre for Evidence-based Medicine. 18 
Statistical analysis
Two investigators (JFS and RV) performed data extraction, including: age; sex; year of diagnosis; first and second eye laterality; sites of uveal involvement; interval to second eye involvement; diagnostic modality; tumour histology, pigmentation, LBD and thickness; presence of pre-existing uveal nevi or oculodermal melanocytosis; treatment; locoregional recurrence; distant metastases; cause of death and follow-up. Melanoma staging was adopted from the American Joint Committee on Cancer 7th Edition. 19 Demographics, clinicopathological characteristics and treatments were assessed for differences in distribution between patients with bilateral UM and unilateral UM and between the first and second affected eye in bilateral UM. Statistical analyses were performed using a Student's t-test for continuous variables and a chi-square or Fisher's exact test (as appropriate) for categorical variables. A KaplanMeier curve was generated for all survival analyses and a log-rank test was used to assess for differences in survival curves. Unknown, unspecified or incomplete data were excluded from statistical analyses. All statistical analyses were two-sided and a P value <0.05 was considered statistically significant.
RESULTS
A total of 52 cases of primary bilateral UM were identified from the three combined data sources.
One case was identified at UHCMC from 1996 to 2016. Out of a total of 8920 cases of UM identified in the SEER-18 database from 1973 to 2013, five cases met criteria for primary bilateral UM (0.06%).
The remaining 8915 cases of unilateral UM served as a comparison group. The literature search yielded 796 articles, containing 32 articles describing primary bilateral UM, 506 duplicate articles, 27 nonEnglish articles and 231 articles not describing primary bilateral UM (Fig. 1 ). Five additional articles were obtained from hand review of references. Of the 37 full text articles screened for eligibility, 25 articles describing 46 total cases of primary bilateral UM met inclusion criteria and were included in the analysis. Table 1 provides an overview of the 46 cases of primary bilateral UM reported from eight countries described in the English language literature between 1950 and 2016. 14, Case reports comprised the largest percentage of studies (72.0%), and the largest case series described eight patients.
14 No case control studies, systematic reviews or randomized controlled trials were identified. The majority of studies contained information on clinicopathological characteristics of both primary tumours (n = 19), metastases at diagnosis (n = 25) and treatments (n = 25). Few studies had information regarding known clinical prognostic factors for UM, including race (n = 6), atypical cutaneous nevi (n = 0), freckles (n = 0), iris nevi (n = 1), occupation (n = 2) and symptoms at presentation (n = 11).
When combining cases from the three data sources, patients with primary bilateral UM and unilateral UM were similar with regard to sex, race Age for n > 1 patients represents the mean. C, choroid; CB, ciliary body; CR, case report; CS, case series; F, female; I, iris; L, left; LBD, largest basal diameter; M, male; mm, millimetres; mo, months; n, number; NOS, not otherwise specified; R, right; Th, thickness.
and age at diagnosis (Table 2) . Whereas unilateral UM equally affected the right and left eye, bilateral UM more commonly affected the right eye first, but this trend was not statistically significant when compared to unilateral UM patients (P = 0.09). Preexisting ocular nevi or oculodermal melanocytosis were present in 11.8% of bilateral UM patients identified from the literature search. There were no differences in site of uveal involvement, tumour histology, tumour stage or the presence of distant metastases at diagnosis in patients with bilateral UM as compared to unilateral UM (P > 0.05 for all). Additionally, patients with bilateral UM and unilateral UM were treated similarly with surgery and/or radiation (P = 0.13) and the mean follow-up time was similar (P = 0.26). Regarding prognosis, there were no differences in overall survival between patients with unilateral UM and bilateral UM when considering survival from diagnosis of the first affected eye ( Fig. 2a ; median overall survival 149 months vs. 130 months, respectively; logrank P = 0.93), or survival from diagnosis of the second affected eye ( Fig. 2b ; median overall survival 65 months vs. 130 months, respectively; log-rank P = 0.21).
Among patients with primary bilateral UM, 68.6% presented with unilateral disease and subsequently developed bilateral disease at a median interval of 22 months (range 0-384 months). The site of uveal involvement, as well as tumour histology, size and pigmentation, did not differ between the first and second affected eyes in patients with bilateral UM (Table 3 ; P > 0.05 for all). However, the first affected eye was more likely to be treated with enucleation (P = 0.002), while the second affected eye was more likely to be treated in a globe Unknown or incomplete data were excluded from statistical analyses. Percentages are based on the total number of cases with known data.
† Corresponds to the first affected eye in patients with bilateral uveal melanoma. ‡ Corresponds to patients with unilateral presentations only. mo, months; n, number; NA, not applicable; y, years.
sparing fashion with radioactive plaque, proton beam radiation, local resection, photocoagulation or thermotherapy (Table 3 ). There were no differences in OS between patients presenting simultaneously with bilateral disease or between patients presenting with unilateral disease and subsequently developing bilateral disease ( Fig. 2c ; log-rank P = 0.88). There were also no differences in overall survival between patients who developed bilateral disease less than or greater than 2 years after the diagnosis of the first UM ( Fig. 2d ; P = 0.72).
DISCUSSION
Primary bilateral UM is a rare and incompletely described entity in the literature. Herein, we provide the largest analysis of patients with primary bilateral UM to date, combining cases from an institutional database, a population-based cancer registry, and a systematic review of the literature. Our results demonstrate that patients with primary bilateral UM are demographically similar to unilateral UM patients, with a median time interval between development of the first and second UM of approximately 2 years.
Larger tumour size, pigmentation and involvement of the ciliary body are all clinicopathological characteristics associated with a poorer prognosis for unilateral UM. [10] [11] [12] [13] Specifically, increasing LBD and tumour thickness are the most important predictors of an increased risk for metastases. 13 This present analysis demonstrates that similar prognostic factors also apply to bilateral UM patients. Patients with bilateral UM and unilateral UM presented with comparably staged tumours involving similar anatomic sites and the clinicopathological characteristics of the two UM did not differ. Small sample sizes did not allow survival analyses based on anatomic site of involvement or tumour size.
Locoregional control with surgery and radiation has not improved survival in unilateral UM, resulting in 5-and 10-year overall survival of approximately 75% and 60%, respectively. [44] [45] [46] This present study demonstrates that patients with bilateral UM Figure 2 . Kaplan-Meier overall survival curves for patients with unilateral and bilateral uveal melanoma, considering survival of bilateral uveal melanoma patients from diagnosis of the (a) first affected eye and (b) second affected eye and survival of bilateral uveal melanoma patients (c) presenting simultaneously or sequentially with bilateral disease, as well as (d) developing bilateral disease less than or greater than 2 years from initial diagnosis.
have similar survival as unilateral UM patients, with 5-and 10-year overall survival of 81% and 57.9%, respectively. Moreover, distant metastases remain the leading cause of death in UM as up to 50% of patients will ultimately develop metastatic disease. 47 In the follow-up period of our study, 20% of bilateral UM patients developed distant metastases and these were reported to contribute to 53.3% of total deaths. Our study also supports the liver being the most common site for UM metastases, accounting for two-thirds of known metastatic sites in bilateral UM patients. 46 Additionally, there were no survival differences for bilateral UM patients presenting with bilateral or unilateral disease, nor between patients subsequently developing bilateral disease greater than 2 years after the initial UM diagnosis, both of which suggest that bilateral disease does not appear to present in a more aggressive fashion than unilateral disease. While approximately half of bilateral UM patients were initially treated with enucleation, globe-sparing treatments were likely selected upon the presentation of bilateral disease in an effort to preserve vision and minimize morbidity.
Theoretically, bilateral UM could result from metastases from a non-ocular primary site or from UM to the contralateral eye. 48, 49 In our study, we excluded cases in which metastases from an ocular or non-ocular site were clinically feasible; for example, if a patient had a known non-ocular melanoma diagnosed prior to the UM. In addition, bilateral diffuse uveal melanocytic proliferation is a welldefined paraneoplastic syndrome that can mimic bilateral UM. 17 As such, we also excluded patients with concurrent or antecedent non-ocular malignancy in which diffuse uveal melanocytic proliferation was plausible. Therefore, the cohort of bilateral UM patients included in the present study has a high likelihood of representing true cases of primary bilateral disease.
There are a number of limitations of this study. Publication and language biases are possible given the exclusion of non-English language studies. The data were retrospectively collected and combining cases from three different data sources over 60 years, including a publicly available database, lends itself to underreporting and varying degrees of data Unknown or incomplete data were excluded from statistical analyses. Percentages are based on the total number of cases with known data. † local resection, photocoagulation, thermotherapy. LBD, largest basal diameter; mm, millimetres; n, number.
quality. Notably, very few of the included studies contained information on known prognostic factors for unilateral UM, including race, the presence of atypical cutaneous nevi, freckles, occupation, and the presence of symptoms on presentation. We were also unable to analyse other risk factors for bilateral UM, including the presence of a nevus of Ota or BAP1 mutation. Finally, given the lack of a comparison group for the cases identified in the systematic review, we could not address the risk of developing bilateral disease in patients presenting with unilateral disease.
Unique limitations of the SEER population registry should also be mentioned. SEER does not differentiate between the ciliary body and iris as coded primary sites, so ciliary body involvement could not be specifically compared between unilateral UM and bilateral UM patients. Moreover, the small sample size of the bilateral UM cohort limited statistical comparisons for some variables, including site of uveal involvement. Additionally, SEER only records the tumour stage at diagnosis and initial treatment, so the development of locoregional recurrence or distant disease could not be assessed. Finally, SEER does not provide information related to the specific types of treatments. Therefore, differences in the type of surgery or radiation therapy could act as confounding variables and impact overall survival. Further studies comparing specific treatments between patients with bilateral UM and unilateral UM will be required to determine the influence of treatment on overall survival. This present study emphasizes the importance of considering the concurrent presentation or subsequent development, of bilateral disease in any patient presenting with unilateral UM. It also demonstrates that the development of bilateral disease does not portend a poorer prognosis. The phenomenon of UM occurring in a paired organ suggests a genetic predisposition to developing UM, and the incidence of primary bilateral UM is reported to be higher than expected by chance alone.
14 Recently, however, a patient with primary bilateral UM displayed chromosomal aneuploidy suggestive of discordant BAP1 expression in each affected eye. 43 Thus, additional studies utilizing genetic testing of paired tumours are required to determine if primary bilateral UM represents a true genetic tendency to developing bilateral disease, or if the development of primary bilateral UM represents an under-appreciated stochastic event in the natural history of UM.
